In The News: March 2013

The U.S. Food and Drug Administration approved a drug by the name of Xeljanz (tofacitinib) as an alternative to methotrexate for the severe pain caused by rheumatoid arthritis (RA).
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access